Xu Jin-Zhi, Wang Wen-Quan, Zhang Wu-Hu, Xu Hua-Xiang, Gao He-Li, Zhang Shi-Rong, Wu Chun-Tao, Li Shuo, Li Hao, Xu Jin, Yu Xian-Jun, Liu Liang
Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
J Cancer. 2019 Jul 10;10(17):4123-4131. doi: 10.7150/jca.30883. eCollection 2019.
: Pancreatic ductal adenocarcinoma (PDAC) progression is mediated by mutations in driver genes and a complex stroma that is mainly dependent on the Sonic hedgehog (Shh) signaling pathway. However, the association between driver genes and Shh-pathway proteins and their potential prognostic significance remain unclear. : We analyzed protein expressions of the , and driver genes and the Shh-pathway molecules, including Shh, glioma-associated oncogene (Gli) 1, Gli2, and smoothened (SMO) by immunohistochemistry using tissue microarrays in 237 patients with resectable PDAC and statistically determined their prognostic significance. : mutation was associated with shorter survival outcomes [overall survival (OS): Hazard ratio (HR) 1.887, < 0.001]; recurrence-free survival (RFS): HR 1.886, < 0.001) and abnormal p53 immunolabeling was associated with poor OS (HR 1.436, = 0.011) in patients with PDAC. The mutational status of p16 had no effect on patient survival. High levels of SMO and Gli1 expression were associated with poor survival outcomes in both univariate and multivariate analyses. Pearson's χ test showed a medium correlation between the mutation and Shh (R = 0.343) and Gli1 (R = 0.505) expression levels ( < 0.001). Patients with the mutation and high levels of Shh and Gli1 expression showed the poorest survival outcomes (RFS: HR 2.976; OS: HR 3.598; < 0.001 for both) compared with other patients in the study. : Loss of associated with a strongly activated Shh pathway resulted in poor survival outcomes in patients with resected PDAC.
胰腺导管腺癌(PDAC)的进展由驱动基因突变和主要依赖于音猬因子(Shh)信号通路的复杂基质介导。然而,驱动基因与Shh通路蛋白之间的关联及其潜在的预后意义仍不清楚。我们通过免疫组织化学方法,利用组织芯片分析了237例可切除PDAC患者中 、 和 驱动基因以及Shh通路分子(包括Shh、胶质瘤相关癌基因(Gli)1、Gli2和平滑肌样蛋白(SMO))的蛋白表达,并通过统计学方法确定了它们的预后意义。 在PDAC患者中, 突变与较短的生存结局相关[总生存期(OS):风险比(HR)1.887, < 0.001];无复发生存期(RFS):HR 1.886, < 0.001),且p53免疫标记异常与较差的OS相关(HR 1.436, = 0.011)。p16的突变状态对患者生存无影响。在单因素和多因素分析中,高水平的SMO和Gli1表达均与较差的生存结局相关。Pearson卡方检验显示, 突变与Shh(R = 0.343)和Gli1(R = 0.505)表达水平之间存在中等程度的相关性( < 0.001)。与研究中的其他患者相比,具有 突变且Shh和Gli1表达水平高的患者生存结局最差(RFS:HR 2.976;OS:HR 3.598;两者均 < 0.001)。与Shh通路强烈激活相关的 缺失导致切除的PDAC患者生存结局较差。